Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 20/20 | 0.57 |
| ▸ | PPARA | Q07869 | 15/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | PPARD | Q03181 | 5/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2787459 | 0.85 | PPARG (0.44) | PPARGPPARACYP3A4CYP2C9KCNH2 | |
| SCHEMBL5278893 | 0.83 | PPARG (0.58) | PPARGPPARACYP3A4CYP2C9KCNH2 | |
| SCHEMBL4283015 | 0.81 | PPARG (0.63) | PPARGPPARACYP3A4CYP2C9KCNH2 | |
| SCHEMBL170065 | 0.81 | PPARG (0.63) | PPARGPPARACYP3A4CYP2C9KCNH2 | |
| SCHEMBL10367689 | 0.79 | PPARG (0.60) | PPARGPPARACYP3A4CYP2C9KCNH2 | |
| SCHEMBL6052101 | 0.78 | PPARG (0.61) | PPARGPPARACYP3A4CYP2C9KCNH2 | |
| SCHEMBL3279259 | 0.76 | PPARG (0.72) | PPARGPPARAPPARD | |
| Reglitazar SCHEMBL14544595 | 0.76 | PPARG (0.61) | PPARGPPARACYP3A4CYP2C9KCNH2 | |
| SCHEMBL7909689 | 0.76 | PPARG (0.63) | PPARGPPARACYP3A4CYP2C9KCNH2 | |
| Reglitazar SCHEMBL362873 | 0.76 | PPARG (0.61) | PPARGPPARACYP3A4CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060030597-A1 | Method of inhibiting angiogenesis | GERRITSEN MARY E | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030597-A1 | Method of inhibiting angiogenesis | PPARG, PPARA, RXRG | PPARG 1/4885PPARA 2/4885CYP3A4 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.